Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
ACS Omega ; 5(5): 2107-2113, 2020 Feb 11.
Article in English | MEDLINE | ID: mdl-32064371

ABSTRACT

The influence of different reaction conditions on the yield of syringaldehyde was studied by using perovskite oxide as the catalyst. The optimal reaction conditions are as follows: 0.60 g of dealkali lignin, 0.60 g of 5 wt % theta ring-loaded LaFe0.2Cu0.8O3 catalyst, 30 mL of 1.0 mol/L NaOH solution, 160 °C reaction temperature, 0.80 MPa O2 pressure, and 2.5 h reaction time. Under these conditions, the highest syringaldehyde yield was 10.00%. The recycling performance of the catalyst was studied. It was found by XRD analysis that the catalyst maintained high catalytic activity after four times of use.

2.
Int J Mol Med ; 43(4): 1769-1777, 2019 Apr.
Article in English | MEDLINE | ID: mdl-30720058

ABSTRACT

Alzheimer's disease (AD) is one of the most frequent diseases in elderly people and causes high mortality. Its incidence is increasing annually and no effective therapeutic treatment currently exists. In the present study, salidroside, a major active ingredient of Rhodiola rosea, was able to protect PC­12 cells from the toxicity and apoptosis induced by AD inducer amyloid (A)ß1­42. Salidroside significantly protected PC­12 cells by inhibiting Aß1­42­induced cytotoxicity and mitochondria­mediated endogenous caspase apoptotic pathways. Mechanistic studies demonstrated that salidroside significantly activated the extracellular signal regulated kinase (ERK)1/2 and protein kinase B (AKT) signaling pathways. This observation was further confirmed using the ERK1/2 inhibitor PD98059 and the AKT inhibitor LY294002, which demonstrated that salidroside promoted PC­12 cell survival and proliferation by activating the ERK1/2 and AKT signaling pathways. Salidroside is a therapeutic candidate for the treatment of AD and provides a basis for further drug development.


Subject(s)
Amyloid beta-Peptides/toxicity , Apoptosis/drug effects , Cytoprotection/drug effects , Glucosides/pharmacology , Neuroprotective Agents/pharmacology , Phenols/pharmacology , Animals , Caspase 3/metabolism , Caspase 7/metabolism , Glucosides/chemistry , L-Lactate Dehydrogenase/metabolism , MAP Kinase Signaling System/drug effects , Malondialdehyde/metabolism , Membrane Potential, Mitochondrial/drug effects , Mitochondria/drug effects , Mitochondria/metabolism , PC12 Cells , Phenols/chemistry , Phosphorylation/drug effects , Proto-Oncogene Proteins c-akt/metabolism , Rats , Reactive Oxygen Species/metabolism , Superoxide Dismutase/metabolism
3.
J Zhejiang Univ Sci B ; 19(12): 924-934, 2018.
Article in English | MEDLINE | ID: mdl-30507076

ABSTRACT

The purpose of this study was to explore the differences in interhemispheric functional connectivity in patients with Alzheimer's disease (AD) and amnestic mild cognitive impairment (aMCI) based on a triple network model consisting of the default mode network (DMN), salience network (SN), and executive control network (ECN). The technique of voxel-mirrored homotopic connectivity (VMHC) analysis was applied to explore the aberrant connectivity of all patients. The results showed that: (1) the statistically significant connections of interhemispheric brain regions included DMN-related brain regions (i.e. precuneus, calcarine, fusiform, cuneus, lingual gyrus, temporal inferior gyrus, and hippocampus), SN-related brain regions (i.e. frontoinsular cortex), and ECN-related brain regions (i.e. frontal middle gyrus and frontal inferior); (2) the precuneus and frontal middle gyrus in the AD group exhibited lower VMHC values than those in the aMCI and healthy control (HC) groups, but no significant difference was observed between the aMCI and HC groups; and (3) significant correlations were found between peak VMHC results from the precuneus and Mini Mental State Examination (MMSE) and Montreal Cognitive Scale (MOCA) scores and their factor scores in the AD, aMCI, and AD plus aMCI groups, and between the results from the frontal middle gyrus and MOCA factor scores in the aMCI group. These findings indicated that impaired interhemispheric functional connectivity was observed in AD and could be a sensitive neuroimaging biomarker for AD. More specifically, the DMN was inhibited, while the SN and ECN were excited. VMHC results were correlated with MMSE and MOCA scores, highlighting that VMHC could be a sensitive neuroimaging biomarker for AD and the progression from aMCI to AD.


Subject(s)
Alzheimer Disease/physiopathology , Cognitive Dysfunction/physiopathology , Aged , Aged, 80 and over , Brain/diagnostic imaging , Brain Mapping , Female , Humans , Magnetic Resonance Imaging , Male , Memory , Middle Aged , Models, Neurological , Nerve Net
4.
Biomed Pharmacother ; 78: 60-65, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26898425

ABSTRACT

CONTEXT: Wuling mycelia powder is the dry powder of rare a fungi Xyla ria sp., Carbon species, with a long history of medicinal use in Chinese medicine. Recently it has shown a powerful antidepressant activity in clinic. OBJECTIVE: The present study explores the antidepressant activity of Wuling mycelia powder in chronic unpredictable mild stress (CUMS) rats and its possible involvement of l-arginine-nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) signaling pathway. MATERIALS AND METHODS: Experiments were performed in the rat CUMS model. CUMS rats were treated with Wuling mycelia powder (0.5, 1.0 or 2.0 g/kg, i.g.) to test behavioral changes including the sucrose preference, the crossing number and food consumption. Further, L-arginine (substrate for nitric oxide) (750 mg/kg), 7-nitroindazole (a specific neuronal nitric oxide synthase inhibitor) (25 mg/kg), sildenafil (phosphodiesterase 5 inhibitor) (5 mg/kg) and methylene blue (direct inhibitor of both nitric oxide synthase and soluble guanylate cyclase) (10 mg/kg) were treated for 60 min before each test to detect the possible mechanism of antidepressant-like effect of Wuling mycelia powder. RESULTS: After 4 weeks of administration, both 1.0 or 2.0 g/kg Wuling mycelia powder suppressed the behavioral changes including the sucrose preference [F(3, 31)=50.87, p<0.001], the crossing number [F(3, 31)=68.98, p<0.05], and food consumption [F(3, 31)=19.04, p<0.05] in the CUMS rats. The antidepressant-like effect of Wuling mycelia powder was prevented by pretreatment with l-arginine and sildenafil. Pretreatment of rats with 7-nitroindazole and methylene blue potentiated the effect of Wulin mycelia powder. DISCUSSION AND CONCLUSION: Our findings demonstrate that Wuling mycelia powder has an antidepressant-like effect in the CUMS rats, and possible involvement of L-arginine-nitric oxide-cyclic GMP signaling pathway in its antidepressant effect.


Subject(s)
Antidepressive Agents/pharmacology , Arginine/metabolism , Cyclic GMP/metabolism , Drugs, Chinese Herbal/chemistry , Mycelium/chemistry , Nitric Oxide/metabolism , Signal Transduction/drug effects , Animals , Antidepressive Agents/therapeutic use , Disease Models, Animal , Dose-Response Relationship, Drug , Feeding Behavior/drug effects , Food Preferences , Hippocampus/drug effects , Hippocampus/pathology , Indazoles/chemistry , Male , Methylene Blue/chemistry , Powders , Rats, Sprague-Dawley , Sildenafil Citrate/chemistry , Stress, Psychological/drug therapy , Sucrose
5.
Biomed Environ Sci ; 25(6): 697-705, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23228840

ABSTRACT

OBJECTIVE: To study the contribution of executive function to abnormal recognition of facial expressions of emotion in schizophrenia patients. METHODS: Abnormal recognition of facial expressions of emotion was assayed according to Japanese and Caucasian facial expressions of emotion (JACFEE), Wisconsin card sorting test (WCST), positive and negative symptom scale, and Hamilton anxiety and depression scale, respectively, in 88 paranoid schizophrenia patients and 75 healthy volunteers. RESULTS: Patients scored higher on the Positive and Negative Symptom Scale and the Hamilton Anxiety and Depression Scales, displayed lower JACFEE recognition accuracies and poorer WCST performances. The JACFEE recognition accuracy of contempt and disgust was negatively correlated with the negative symptom scale score while the recognition accuracy of fear was positively with the positive symptom scale score and the recognition accuracy of surprise was negatively with the general psychopathology score in patients. Moreover, the WCST could predict the JACFEE recognition accuracy of contempt, disgust, and sadness in patients, and the perseverative errors negatively predicted the recognition accuracy of sadness in healthy volunteers. The JACFEE recognition accuracy of sadness could predict the WCST categories in paranoid schizophrenia patients. CONCLUSION: Recognition accuracy of social-/moral emotions, such as contempt, disgust and sadness is related to the executive function in paranoid schizophrenia patients, especially when regarding sadness.


Subject(s)
Executive Function , Facial Expression , Schizophrenia, Paranoid/psychology , Adolescent , Adult , Asian People , Female , Humans , Male , Middle Aged , White People , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...